Trials / Completed
CompletedNCT00541489
Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip
A 13-Week, Phase 3, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo Bid and Naproxen 500 mg Bid, Controlled Study on the Efficacy on Signs and Symptoms, and Safety of Naproxcinod (HCT3012) 750 mg Bid, in Patients With Osteoarthritis of the Hip
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- Sponsor
- NicOx · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
To study the efficacy and safety of Naproxcinod vs. Placebo and Naproxen in the treatment of signs and symptoms of Osteoarthritis.
Detailed description
This is a 13 week randomized, double-blind, parallel group, multicenter study comparing efficacy and safety of Naproxcinod, Placebo and Naproxen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Naproxcinod | 750 mg, bid |
| DRUG | Naproxen | 500 mg, bid |
| DRUG | Placebo | bid |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-09-01
- First posted
- 2007-10-10
- Last updated
- 2009-02-20
Locations
48 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00541489. Inclusion in this directory is not an endorsement.